Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL

Andrea Gallina, Claudio Jeldres, Felix K H Chun, Shahrokh F. Shariat, Alberto Briganti, Jochen Walz, Claus Roehrborn, Fred Saad, Hartwig Huland, Markus Graefen, Francesco Montorsi, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: We hypothesized that either very low (0-2.5 ng/mL) or very high (>20 ng/mL) PSA values may limit the accuracy of pathological stage predictions. To test this hypothesis, we examined 5193 consecutive patients subjected to radical prostatectomy (RP) for localized prostate cancer (PCa). Material and methods: Patients were divided into three cohorts according to their pre-treatment PSA value: ≤2.5 (n = 331), 2.51-20 (n = 4545) and >20 ng/mL (n = 317). Subsequently in each cohort, the ability of PSA, clinical stage and biopsy Gleason sum was tested in multivariable logistic regression models predicting three separate endpoints: extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph node invasion (LNI). Predictive accuracy represented the performance benchmark. All models were adjusted for year of surgery and subjected to 200 bootstrap resamples to reduce overfit bias. Results: For PSA ≤2.5 ng/mL, predictive accuracy was 76.7%, 72.3% and 82.8% for respectively ECE, SVI and LNI. For PSA 2.51-20 ng/mL, the predictive accuracy for the same endpoints was 67.8%, 77.4% and 81.6%. Finally, for PSA >20 ng/mL, predictive accuracy was 63.6%, 63.7% and 70.6%. Conclusions: The ability to predict pathological stage in patients with PSA values in excess of 20 ng/mL significantly decreased, compared to patients with lower PSA values. Therefore, accurate staging of these patients may require alternative markers or staging schemes.

Original languageEnglish (US)
Pages (from-to)1374-1380
Number of pages7
JournalEuropean Urology
Volume52
Issue number5
DOIs
StatePublished - Nov 2007

Fingerprint

Seminal Vesicles
Logistic Models
Lymph Nodes
Benchmarking
Prostatectomy
Prostatic Neoplasms
menthyl 3-(2-pyridylsulfinyl)acrylate
Biopsy
Therapeutics

Keywords

  • Extreme PSA values
  • Partin stages
  • Prediction
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Gallina, A., Jeldres, C., Chun, F. K. H., Shariat, S. F., Briganti, A., Walz, J., ... Karakiewicz, P. I. (2007). Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL. European Urology, 52(5), 1374-1380. https://doi.org/10.1016/j.eururo.2006.12.010

Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL. / Gallina, Andrea; Jeldres, Claudio; Chun, Felix K H; Shariat, Shahrokh F.; Briganti, Alberto; Walz, Jochen; Roehrborn, Claus; Saad, Fred; Huland, Hartwig; Graefen, Markus; Montorsi, Francesco; Karakiewicz, Pierre I.

In: European Urology, Vol. 52, No. 5, 11.2007, p. 1374-1380.

Research output: Contribution to journalArticle

Gallina, A, Jeldres, C, Chun, FKH, Shariat, SF, Briganti, A, Walz, J, Roehrborn, C, Saad, F, Huland, H, Graefen, M, Montorsi, F & Karakiewicz, PI 2007, 'Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL', European Urology, vol. 52, no. 5, pp. 1374-1380. https://doi.org/10.1016/j.eururo.2006.12.010
Gallina A, Jeldres C, Chun FKH, Shariat SF, Briganti A, Walz J et al. Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL. European Urology. 2007 Nov;52(5):1374-1380. https://doi.org/10.1016/j.eururo.2006.12.010
Gallina, Andrea ; Jeldres, Claudio ; Chun, Felix K H ; Shariat, Shahrokh F. ; Briganti, Alberto ; Walz, Jochen ; Roehrborn, Claus ; Saad, Fred ; Huland, Hartwig ; Graefen, Markus ; Montorsi, Francesco ; Karakiewicz, Pierre I. / Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL. In: European Urology. 2007 ; Vol. 52, No. 5. pp. 1374-1380.
@article{940c4c20dacf45d5962d7ec43060684a,
title = "Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL",
abstract = "Introduction: We hypothesized that either very low (0-2.5 ng/mL) or very high (>20 ng/mL) PSA values may limit the accuracy of pathological stage predictions. To test this hypothesis, we examined 5193 consecutive patients subjected to radical prostatectomy (RP) for localized prostate cancer (PCa). Material and methods: Patients were divided into three cohorts according to their pre-treatment PSA value: ≤2.5 (n = 331), 2.51-20 (n = 4545) and >20 ng/mL (n = 317). Subsequently in each cohort, the ability of PSA, clinical stage and biopsy Gleason sum was tested in multivariable logistic regression models predicting three separate endpoints: extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph node invasion (LNI). Predictive accuracy represented the performance benchmark. All models were adjusted for year of surgery and subjected to 200 bootstrap resamples to reduce overfit bias. Results: For PSA ≤2.5 ng/mL, predictive accuracy was 76.7{\%}, 72.3{\%} and 82.8{\%} for respectively ECE, SVI and LNI. For PSA 2.51-20 ng/mL, the predictive accuracy for the same endpoints was 67.8{\%}, 77.4{\%} and 81.6{\%}. Finally, for PSA >20 ng/mL, predictive accuracy was 63.6{\%}, 63.7{\%} and 70.6{\%}. Conclusions: The ability to predict pathological stage in patients with PSA values in excess of 20 ng/mL significantly decreased, compared to patients with lower PSA values. Therefore, accurate staging of these patients may require alternative markers or staging schemes.",
keywords = "Extreme PSA values, Partin stages, Prediction, Radical prostatectomy",
author = "Andrea Gallina and Claudio Jeldres and Chun, {Felix K H} and Shariat, {Shahrokh F.} and Alberto Briganti and Jochen Walz and Claus Roehrborn and Fred Saad and Hartwig Huland and Markus Graefen and Francesco Montorsi and Karakiewicz, {Pierre I.}",
year = "2007",
month = "11",
doi = "10.1016/j.eururo.2006.12.010",
language = "English (US)",
volume = "52",
pages = "1374--1380",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20 ng/mL

AU - Gallina, Andrea

AU - Jeldres, Claudio

AU - Chun, Felix K H

AU - Shariat, Shahrokh F.

AU - Briganti, Alberto

AU - Walz, Jochen

AU - Roehrborn, Claus

AU - Saad, Fred

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Montorsi, Francesco

AU - Karakiewicz, Pierre I.

PY - 2007/11

Y1 - 2007/11

N2 - Introduction: We hypothesized that either very low (0-2.5 ng/mL) or very high (>20 ng/mL) PSA values may limit the accuracy of pathological stage predictions. To test this hypothesis, we examined 5193 consecutive patients subjected to radical prostatectomy (RP) for localized prostate cancer (PCa). Material and methods: Patients were divided into three cohorts according to their pre-treatment PSA value: ≤2.5 (n = 331), 2.51-20 (n = 4545) and >20 ng/mL (n = 317). Subsequently in each cohort, the ability of PSA, clinical stage and biopsy Gleason sum was tested in multivariable logistic regression models predicting three separate endpoints: extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph node invasion (LNI). Predictive accuracy represented the performance benchmark. All models were adjusted for year of surgery and subjected to 200 bootstrap resamples to reduce overfit bias. Results: For PSA ≤2.5 ng/mL, predictive accuracy was 76.7%, 72.3% and 82.8% for respectively ECE, SVI and LNI. For PSA 2.51-20 ng/mL, the predictive accuracy for the same endpoints was 67.8%, 77.4% and 81.6%. Finally, for PSA >20 ng/mL, predictive accuracy was 63.6%, 63.7% and 70.6%. Conclusions: The ability to predict pathological stage in patients with PSA values in excess of 20 ng/mL significantly decreased, compared to patients with lower PSA values. Therefore, accurate staging of these patients may require alternative markers or staging schemes.

AB - Introduction: We hypothesized that either very low (0-2.5 ng/mL) or very high (>20 ng/mL) PSA values may limit the accuracy of pathological stage predictions. To test this hypothesis, we examined 5193 consecutive patients subjected to radical prostatectomy (RP) for localized prostate cancer (PCa). Material and methods: Patients were divided into three cohorts according to their pre-treatment PSA value: ≤2.5 (n = 331), 2.51-20 (n = 4545) and >20 ng/mL (n = 317). Subsequently in each cohort, the ability of PSA, clinical stage and biopsy Gleason sum was tested in multivariable logistic regression models predicting three separate endpoints: extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph node invasion (LNI). Predictive accuracy represented the performance benchmark. All models were adjusted for year of surgery and subjected to 200 bootstrap resamples to reduce overfit bias. Results: For PSA ≤2.5 ng/mL, predictive accuracy was 76.7%, 72.3% and 82.8% for respectively ECE, SVI and LNI. For PSA 2.51-20 ng/mL, the predictive accuracy for the same endpoints was 67.8%, 77.4% and 81.6%. Finally, for PSA >20 ng/mL, predictive accuracy was 63.6%, 63.7% and 70.6%. Conclusions: The ability to predict pathological stage in patients with PSA values in excess of 20 ng/mL significantly decreased, compared to patients with lower PSA values. Therefore, accurate staging of these patients may require alternative markers or staging schemes.

KW - Extreme PSA values

KW - Partin stages

KW - Prediction

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=34548843881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548843881&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2006.12.010

DO - 10.1016/j.eururo.2006.12.010

M3 - Article

C2 - 17174466

AN - SCOPUS:34548843881

VL - 52

SP - 1374

EP - 1380

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -